Premium
Longitudinal changes of mtDNA A3243G mutation load and level of functioning in MELAS
Author(s) -
Mehrazin Mahsa,
Shanske Sara,
Kaufmann Petra,
Wei Ying,
Coku Jorida,
Engelstad Kristin,
Naini Ali,
De Vivo Darryl C.,
DiMauro Salvatore
Publication year - 2009
Publication title -
american journal of medical genetics part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.064
H-Index - 112
eISSN - 1552-4833
pISSN - 1552-4825
DOI - 10.1002/ajmg.a.32703
Subject(s) - mitochondrial dna , melas syndrome , lactic acidosis , asymptomatic , mutation , medicine , mitochondrial disease , polymerase chain reaction , mitochondrial myopathy , point mutation , biology , mutant , mitochondrion , asymptomatic carrier , genetics , endocrinology , physiology , gene
Mitochondrial encephalopathy, lactic acidosis, and stroke‐like episodes (MELAS), one of the most common mitochondrial multisystemic diseases, is most commonly associated with an A‐to‐G transition at nucleotide position 3243 (A3243G) in mitochondrial DNA. We studied 34 individuals harboring the A3243G mutation for up to 7 years; 17 had the full MELAS phenotype and 17 who were classified as “carrier relatives” because they were either asymptomatic or had some symptoms suggestive of mitochondrial disease but no seizures or strokes. Using the sensitive real‐time polymerase chain reaction to quantify the A3243G mutation, we confirmed that the percent mutation decreases progressively in DNA isolated from blood: the average percent decrease was 0.5% per year for fully symptomatic patients and 0.2% per year for oligosymptomatic carrier relatives. We also correlated mutant loads with functional status estimated by the Karnofksky score: even though the mutation load decreases, the level of functioning worsens in fully symptomatic patients, whereas the level of functioning of carrier relatives remains largely unchanged. This study suggests that A3243G mutant load in DNA isolated from blood is neither useful for prognosis nor for functional assessment. © 2009 Wiley‐Liss, Inc.